Webinar Date/Time: Tue, Nov 7, 2023 11:00 AM EST
Mutations in the gene encoding for LRRK2 are among the most common causes of familial and sporadic cases of Parkinson’s disease (PD). LRRK2 is, therefore, a promising target in PD treatment. Quantitation of the LRRK2 protein in human CSF is an important diagnostic marker to monitor the impact of a therapeutic against PD. This method demonstrates a SISCAPA technique for the signature peptide quantitation from LRRK2 protein using the M5 microflow system with the SCIEX 7500 system.
Register Free: https://www.biopharminternational.com/bp_w/enhancing-quantitative-sensitivity
Mutations in the gene encoding for leucine-rich repeat kinase 2 (LRRK2) are among the most common causes of familial and sporadic cases of Parkinson’s disease (PD), making LRRK2 a promising target for treating PD. Quantitation of the LRRK2 protein in human cerebrospinal fluid (CSF) is therefore an important diagnostic marker to monitor the impact of a therapeutic against PD. Accurate and sensitive quantitation of LRRK2 in CSF is important to support clinical trials targeting LRRK2 levels.
Building off existing methodologies, Neuron23 collaborated with SCIEX to perform quantitative analysis of LRRK2 in human CSF on an M5 MicroLC system paired with the SCIEX 7500 system. This workflow demonstrated the sensitive quantitation of LRRK2 at 10 pg/mL in human CSF.In this webinar, Dylan Bennett, a scientist at Neuron23, shares the details of this LC-MS/MS methodology for the sensitive analysis of this promising target.
You will learn about:
Who Should Attend:
Dylan Bennett is a Senior Scientist at Neuron23, Inc., where he leads the LC-MS/MS Bioanalytical department. He has over a decade of experience in the biopharmaceutical industry, specializing in LC-MS analysis of small molecules, peptides and biomarkers. His current research supports the development of therapies to treat genetically predefined neuroinflammatory diseases.